» Articles » PMID: 20471507

Basal Bone Phenotype and Increased Anabolic Responses to Intermittent Parathyroid Hormone in Healthy Male COX-2 Knockout Mice

Overview
Journal Bone
Date 2010 May 18
PMID 20471507
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclooxygenase-2 (COX-2) knockout (KO) mice in inbred strains can have renal dysfunction with secondary hyperparathyroidism (HPTH), making direct effects of COX-2 KO on bone difficult to assess. COX-2 KO mice in an outbred CD-1 background did not have renal dysfunction but still had two-fold elevated PTH compared to wild type (WT) mice. Compared to WT mice, KO mice had increased serum markers of bone turnover, decreased femoral bone mineral density (BMD) and cortical bone thickness, but no differences in trabecular bone volume by microCT or dynamic histomorphometry. Because PTH is a potent inducer of COX-2 and prostaglandin (PG) production, we examined the effects of COX-2 KO on bone responses after 3 weeks of intermittent PTH. Intermittent PTH increased femoral BMD and cortical bone area more in KO mice than in WT mice and increased trabecular bone volume in the distal femur in both WT and KO mice. Although not statistically significant, PTH-stimulated increases in trabecular bone tended to be greater in KO mice than in WT mice. PTH increased serum markers of bone formation and resorption more in KO than in WT mice but increased the ratio of osteoblastic surface-to-osteoclastic surface only in KO mice. PTH also increased femoral mineral apposition rates and bone formation rates in KO mice more than in WT mice. Acute mRNA responses to PTH of genes that might mediate some anabolic and catabolic effects of PTH tended to be greater in KO than WT mice. We conclude that (1) the basal bone phenotype in male COX-2 KO mice might reflect HPTH, COX-2 deficiency or both, and (2) increased responses to intermittent PTH in COX-2 KO mice, despite the presence of chronic HPTH, suggest that absence of COX-2 increased sensitivity to PTH. It is possible that manipulation of endogenous PGs could have important clinical implications for anabolic therapy with PTH.

Citing Articles

The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts.

Maranda V, Gaumond M, Moffatt P Int J Mol Sci. 2022; 23(4).

PMID: 35216266 PMC: 8875491. DOI: 10.3390/ijms23042148.


Anabolic actions of PTH in murine models: two decades of insights.

Zweifler L, Koh A, Daignault-Newton S, McCauley L J Bone Miner Res. 2021; 36(10):1979-1998.

PMID: 34101904 PMC: 8596798. DOI: 10.1002/jbmr.4389.


Pyrroloquinoline Quinone Prevents Estrogen Deficiency-Induced Osteoporosis by Inhibiting Oxidative Stress and Osteocyte Senescence.

Geng Q, Gao H, Yang R, Guo K, Miao D Int J Biol Sci. 2019; 15(1):58-68.

PMID: 30662347 PMC: 6329928. DOI: 10.7150/ijbs.25783.


Continuous PTH in Male Mice Causes Bone Loss Because It Induces Serum Amyloid A.

Choudhary S, Santone E, Yee S, Lorenzo J, Adams D, Goetjen A Endocrinology. 2018; 159(7):2759-2776.

PMID: 29757436 PMC: 6692876. DOI: 10.1210/en.2018-00265.


Fibroblast Growth Factor Receptor 3 Deficiency Does Not Impair the Osteoanabolic Action of Parathyroid Hormone on Mice.

Xie Y, Yi L, Weng T, Huang J, Luo F, Jiang W Int J Biol Sci. 2016; 12(8):990-9.

PMID: 27489502 PMC: 4971737. DOI: 10.7150/ijbs.14077.


References
1.
Chikazu D, Li X, Kawaguchi H, Sakuma Y, Voznesensky O, Adams D . Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfa1 binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. 2002. J Bone Miner Res. 2005; 20(10):1888-98. DOI: 10.1359/jbmr.2005.20.10.1887. View

2.
Weinreb M, Suponitzky I, Keila S . Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone. 1997; 20(6):521-6. DOI: 10.1016/s8756-3282(97)00033-1. View

3.
Bellido T, Ali A, Gubrij I, Plotkin L, Fu Q, OBrien C . Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146(11):4577-83. DOI: 10.1210/en.2005-0239. View

4.
Flanagan A, Chambers T . Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinology. 1992; 130(1):443-8. DOI: 10.1210/endo.130.1.1309342. View

5.
Norwood V, Morham S, SMITHIES O . Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int. 2000; 58(6):2291-300. DOI: 10.1046/j.1523-1755.2000.00413.x. View